MADRIGAL PHARMACEUTICALS, INC. (MDGL) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $340.79M; Long-term DebtUSD $340.79M; Long-Term Debt, Maturity, Year OneUSD $30.10M; Long-Term Debt, Maturity, Year TwoUSD $30.18M.
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $340.33M; Long-term DebtUSD $340.33M; Long-Term Debt, Maturity, Year OneUSD $29.98M; Long-Term Debt, Maturity, Year TwoUSD $30.07M.
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $339.88M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $339.88M; Long-Term Debt, Maturity, Year OneUSD $29.89M; Long-Term Debt, Maturity, Year TwoUSD $29.89M.
MADRIGAL PHARMACEUTICALS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount USD | Secured Debt, Current USD | Secured Debt USD | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate, Stated Percentage pure | Notes Payable, Related Parties, Current USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $340.79M | $340.79M | $30.10M | $30.18M | $30.10M | $366.33M | (m) | $15.17M | $471.88M | $9.21M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $340.33M | $340.33M | $29.98M | $30.07M | $29.98M | $366.27M | (m) | $22.59M | $478.89M | $9.67M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $339.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $339.88M | $29.89M | $29.89M | $29.97M | $29.89M | $366.21M | (m) | $485.84M | $10.12M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $339.75M | $339.75M | $31.06M | $31.06M | $31.14M | $31.06M | $366.85M | $7.83M | $498.98M | $10.25M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $118.38M | $118.38M | $11.60M | $126.02M | (m) | (m) | (m) | $5.82M | $143.43M | $2.78M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $118.00M | $118.00M | $11.60M | $126.02M | (m) | (m) | (m) | $8.74M | $146.36M | $3.15M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $117.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $117.57M | $11.62M | $78.79M | $53.11M | (m) | (m) | (m) | $143.51M | $3.58M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $117.09M | $117.09M | $12.18M | $79.20M | (m) | (m) | (m) | $3.07M | $147.69M | $4.07M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $116.61M | $116.61M | $12.77M | $79.60M | (m) | (m) | (m) | $6.40M | $152.16M | $4.54M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $116.14M | $116.14M | $12.77M | $79.60M | (m) | (m) | (m) | $9.62M | $155.38M | $5.02M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $115.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $115.48M | $12.80M | $79.60M | $53.39M | (m) | (m) | (m) | $145.79M | $5.67M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $114.73M | $148.89M | $12.80M | $79.60M | $53.39M | (m) | (m) | $3.10M | (m) | $6.43M | (m) | (m) | $115.00M | 10.95% | (m) |
| 2023-06-30 | $99.25M | $131.66M | $10.88M | $69.04M | $46.36M | (m) | (m) | $5.37M | (m) | $6.10M | (m) | (m) | $100.00M | 10.70% | (m) |
| 2023-03-31 | $83.97M | $113.70M | $9.03M | $58.54M | $39.36M | (m) | (m) | $6.77M | (m) | $5.58M | (m) | (m) | $85.00M | 10.45% | (m) |
| 2022-12-31 | $49.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $69.67M | $5.79M | $5.82M | $34.79M | (m) | (m) | (m) | (m) | $3.39M | (m) | (m) | $50.00M | 11.45% | (m) |
| 2022-09-30 | $48.98M | $67.86M | $5.17M | $10.04M | $51.38M | (m) | (m) | $1.27M | (m) | $3.69M | (m) | (m) | $50.00M | 10.20% | (m) |
| 2022-06-30 | $48.67M | $66.73M | $4.41M | $9.34M | $50.78M | (m) | (m) | $2.20M | (m) | $4.00M | (m) | (m) | $50.00M | 8.70% | (m) |
| 2021-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $10.00K | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.30M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $48.60M |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.61M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $2.31M | $4.61M | (m) | (m) | (m) | (m) | (m) | (m) | $6.91M | $6.91M | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $4.61M | $4.61M | (m) | (m) | (m) | (m) | (m) | (m) | $9.21M | $9.22M | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $6.91M | $4.61M | (m) | (m) | (m) | (m) | (m) | (m) | $9.22M | $11.52M | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $9.21M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $9.21M | $4.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $13.82M | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $2.30M | $9.21M | $4.61M | (m) | (m) | (m) | (m) | (m) | $9.21M | $16.12M | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $4.60M | $9.21M | $4.61M | (m) | (m) | (m) | (m) | (m) | $9.20M | $18.42M | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $6.96M | $9.21M | $4.61M | (m) | (m) | (m) | (m) | (m) | $9.26M | $20.78M | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $9.45M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $9.45M | $9.21M | $4.61M | (m) | (m) | (m) | (m) | (m) | (m) | $23.27M | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | $9.45M | $9.21M | $4.61M | (m) | $233.00K | (m) | (m) | $7.38M | $23.50M | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | $9.46M | $9.21M | $4.60M | (m) | $452.00K | (m) | (m) | $5.31M | $23.72M | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | $9.36M | $9.11M | $4.53M | (m) | $618.00K | (m) | (m) | $3.08M | $23.63M | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $7.92M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | $7.92M | $4.46M | (m) | (m) | $1.97M | (m) | (m) | $7.90M | $14.35M | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | $7.92M | $4.46M | (m) | (m) | $3.93M | (m) | (m) | $7.88M | $16.32M | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $6.05M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.23M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.61M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.09M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.33M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |